Argenx stocks fall as FDA extends review period for subcutaneous efgartigimod

FDA written on wooden cube with keyboard, calculator, chart, glasses.  Business concept

Irina Drozd

Argenx (NASDAQ: ARGX) said the US Food and Drug Administration (FDA) has extended its review of its application for approval of subcutaneous (SC) efgartigimod for the treatment of adult patients with generalized myasthenia gravis (gMG) until June 20.

The company submitted a request

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *